[go: up one dir, main page]

HK1061647A1 - Pharmaceutical compositions of rapmycins - Google Patents

Pharmaceutical compositions of rapmycins Download PDF

Info

Publication number
HK1061647A1
HK1061647A1 HK04104625A HK04104625A HK1061647A1 HK 1061647 A1 HK1061647 A1 HK 1061647A1 HK 04104625 A HK04104625 A HK 04104625A HK 04104625 A HK04104625 A HK 04104625A HK 1061647 A1 HK1061647 A1 HK 1061647A1
Authority
HK
Hong Kong
Prior art keywords
ascomycin
cit
pharmaceutically acceptable
composition
compositions
Prior art date
Application number
HK04104625A
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
HK1061647B (en
Inventor
Dorothea Ledergerber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1061647A1 publication Critical patent/HK1061647A1/en
Publication of HK1061647B publication Critical patent/HK1061647B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (5)

  1. Verwendung eines pharmazeutisch akzeptablen Cellulosederivats zur Inhibition oder Reduktion von Kristallwachstum eines Ascomycins in einer pharmazeutischen Zusammensetzung, die ein Ascomycin in gelöster oder suspendierter Form umfasst.
  2. Verwendung nach Anspruch 1, worin das pharmazeutisch akzeptable Cellulosederivat Hydroxypropylmethylcellulose ist.
  3. Verwendung nach Anspruch 1 oder 2, worin das pharmazeutisch akzeptable Cellulosederivat in einer Menge von 0,1 Gew.-% bis etwa 5 Gew.-%, bezogen auf das Gesamtgewicht der Zusammensetzung, vorhanden ist.
  4. Verwendung nach einem der Ansprüche 1 bis 3, worin das Ascomycin 33-Epichlor-33-desoxyascomycin ist.
  5. Verfahren zur Prävention oder Reduktion von Kristallwachstum eines Ascomycins in einer pharmazeutischen Zusammensetzung, die ein Ascomycin in gelöster oder suspendierter Form umfasst, durch Vermischung dieser Zusammensetzung mit einem pharmazeutisch annehmbaren Cellulosederivat zur Inhibition oder Reduktion von Kristallwachstum post Auflösung oder Suspension.
HK04104625.1A 2001-04-04 2002-04-03 Pharmaceutical compositions of rapmycins HK1061647B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0108498.7 2001-04-04
GBGB0108498.7A GB0108498D0 (en) 2001-04-04 2001-04-04 Organic Compounds
PCT/EP2002/003694 WO2002080978A2 (en) 2001-04-04 2002-04-03 Pharmaceutical compositions comprising ascomycin

Publications (2)

Publication Number Publication Date
HK1061647A1 true HK1061647A1 (en) 2004-09-30
HK1061647B HK1061647B (en) 2007-08-24

Family

ID=

Also Published As

Publication number Publication date
JP4927310B2 (ja) 2012-05-09
AU2002310920A1 (en) 2002-10-21
CA2443235C (en) 2011-03-15
BR0208655A (pt) 2004-03-02
EP1377315B1 (de) 2007-01-03
PT1377315E (pt) 2007-02-28
CN100358580C (zh) 2008-01-02
DE60217315T2 (de) 2007-05-31
WO2002080978A2 (en) 2002-10-17
EP1377315A2 (de) 2004-01-07
WO2002080978A3 (en) 2003-10-30
US20070298058A1 (en) 2007-12-27
CN1226047C (zh) 2005-11-09
ATE350064T1 (de) 2007-01-15
DE60217315D1 (de) 2007-02-15
US20040171599A1 (en) 2004-09-02
US20110224246A1 (en) 2011-09-15
GB0108498D0 (en) 2001-05-23
CN1501814A (zh) 2004-06-02
JP2004525169A (ja) 2004-08-19
CN1679962A (zh) 2005-10-12
CA2443235A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
US9402802B2 (en) Topical compositions comprising ascomycins
EP1147766B1 (de) Arzneimittel
US20110224246A1 (en) Pharmaceutical compositions comprising ascomycin
EP1534339B1 (de) Topische wasser-und ethanolfreie Pimecrolimus enthaltende Zusammensetzungen
HK1061647B (en) Pharmaceutical compositions of rapmycins
HK1040362B (en) Topical compositions comprising ascomycins
MXPA01005514A (en) Topical compositions comprising ascomycins

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130403